Weight loss pill set to rival injections after promising studies

A new daily pill of weight loss has shown promising results in initial studies.

Researchers say that Amycretine, which can be offered by injection or tablet, helped patients lose significant weight in the first trials.

Those who received higher doses of Amycretine as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment, while patients who took daily tablets lost an average of 13.1% of their body weight after 12 weeks.

While weight loss the jabs were greeted as transformers by NHS Managers, injections come with additional work for too stretched health services, so that the forms of drugs for tablets can offer new hope for millions of people seeking to lose weight.

It has been estimated that around 1.5 million British have weight loss, which have been prescribed by specialized weight loss services or private prescriptions.

GPS will be able to distribute next week.

Amycretine, made by Novo Nordiskhelps control blood sugar and appetite by targeting two specific receptors in the body – GLP -1 and the Amyline receiver.

A first trial in 125 adults testing weekly injections of Amycretine, which was published in The Lancet, found that those who took the highest dose (60 mg) lost 24.3% after 36 weeks of treatment. He has also shown signs of improving blood sugar.

Side effects included nausea and vomiting, and were mainly light to moderate and resolved at the end of treatment.

“These phase 1B / 2A data support the potential of subcutaneous Amycretine once a week as therapy for people living with overweight or obesity“Wrote the authors.

“AmyCritine seemed safe and tolerable, and there have been significant reductions in body weight after 36 weeks of treatment.”

The second early trial, published in the same review, evaluated Amycretine in the form of a tablet in 144 people over 12 weeks.

There were light to moderate side effects, including loss of appetite, nausea and vomiting.

The researchers found that people taking the highest dose of 100 mg per day, lost 13.1% of their body weight over four months.

The authors wrote: “Amycretine has effectively lowered body weight and improved metabolic and glycemic parameters in overweight or obesity.

“Longer studies with more participants are justified to assess the safety and efficiency of AMYCritine in individuals living with obesity and Type 2 diabetesAnd to optimize the dose scheme. »»

Studies were also presented at American Diabetes AssociationScientific sessions in Chicago, the United States.

This is a distinct study, which was published at the same meeting, examined the effects of weight loss Jab Wegovy in higher doses.

The researchers found that the granting of patients of 7.2 mg of Wegovy, also known as Sémaglutide, once a week led to an average weight loss of 20.7%, with a third of the participants losing 25% or more of their body weight after 72 weeks.